On June 10, Elevance Health declined 3.3% in regular trading, trading at $407.54/share, with trading volume of $66.61 million.

On the news front, Elevance Health reaffirmed its full-year adjusted earnings guidance of at least $26.75 per diluted share in a regulatory filing, slightly below the FactSet analyst consensus estimate of $26.85. The company also confirmed GAAP diluted EPS guidance of no less than $19.85 for fiscal year 2026. While the shortfall versus consensus is modest at roughly $0.10, the lack of an upward revision disappointed investors seeking positive catalysts.

Sector-wide weakness compounded the selling pressure. Within the Managed Health Care industry, UnitedHealth fell 1.39%, Molina Healthcare dropped 4.33%, Centene declined 3.07%, and Humana lost 0.75%. Notably, JPMorgan recently raised its price target on Elevance Health from $411 to $476 maintaining an overweight rating, and Morgan Stanley lifted its target to $404, suggesting Wall Street maintains a constructive longer-term outlook despite the near-term guidance disappointment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)